NASD · Healthcare · Biotechnology · China
Zai Lab Limited ADR is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Zai Lab Limited ADR is a biopharmaceutical company operating in Greater China and the United States that discovers, develops, and commercializes products for oncology, immunology, neuroscience, and infectious disease. The company has seven approved commercial products marketed in Greater China through partnerships with leading biopharmaceutical firms and internal research capabilities. Its commercial infrastructure covers major medical centers across the region.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Zai Lab Limited ADR stock.
Slightly overvalued: intrinsic value $20.83 per share, market price $22.07, margin of safety -6.0% (as of 2026-10-30).
A 4.2x revenue multiple, discounted for its losses, values the shares at $20.83; the price of $22.07 is 6% above that value.
Leak Score: 45/100 on 8 of 12 signals (On Watch).
1 more funds hold it; the full list is part of the paid plan.
21 more in this industry show a wider margin of safety.
ZLAB is slightly overvalued (as of the 2026-10-30 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $20.83; the price of $22.07 is 6% above that value.
$20.83 per share (as of the 2026-10-30 close), against a market price of $22.07. That is a margin of safety of -6.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
45 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.